JNJ Stock was trading at $164.91 as of 12:24 PM EDT.
The Teligen system from Johnson & Johnson (NYSE:JNJ) has been given 510(k) clearance by the FDA for use in specific spine surgical procedures. Using digital technologies for imaging and access, Teligen, created by J&J’s Orthopaedics division DePuy Synthes, offers minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) surgeries.
According to a press release from the company on Thursday, the system is anticipated to be made accessible in the United States later this year.
“We’re delivering a better field of view to help improve patient care and increase efficiency with our ground-breaking TELIGEN Technology Platform. This development from the DePuy Synthes team and how the VueLIF-T will alter MIS spinal operations make me tremendously proud “said Russell Powers, president of DePuy’s global spine business.
Tuesday’s premarket trade saw shares of Johnson & Johnson (NYSE:JNJ) rise 2.3% toward a two-month high after the pharmaceutical and consumer goods firm reported third-quarter profit and sales that exceeded expectations across all of its business groups. From $3.67 billion, or $1.37 per share, at the same time last year, net income increased to $4.46 billion, or $1.68 per share. Adjusted earnings per share fell to $2.55 from $2.60 when nonrecurring events were excluded, although this was still higher than the FactSet consensus estimate of $2.48.
JNJ Stock: 3 Reasons to Love It
Why is JNJ Stock with such low volatility? Because it’s the closest thing to a perfect recession-resistant investment you can find for income investors.
- recession-proof business strategy
- credit rating is AAA
- Dividend King’s (59-year dividend growth streak)
JNJ Stock is a fantastic ‘Buy’ and ‘Hold’ low volatility dividend king for anyone who has expectations about what its new slower growth and better margin business model likely means for the future. It’s likely that JNJ’s wealthy days are behind it. It will probably take a quarter century to double your money in risk- and inflation-adjusted terms. JNJ Stock can keep you wealthy but won’t make you wealthy
Is Johnson & Johnson (Jnj) Stock Alpha Enough To Make It A Good Low Beta Stock?
Featured Image- Megapixl @ Mesteban100
Author Faith Yakubu